Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus LB
- Development stage
- Phase 4
- Lead developer
- Allergan
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus LB is a probiotic preparation, often heat-treated, composed of a combination of *Lactobacillus fermentum* and *Lactobacillus delbrueckii*. It has demonstrated efficacy and safety in treating acute diarrhea in children and chronic diarrhea in adults. It is also being investigated for its potential in managing Irritable Bowel Syndrome with Diarrhea (IBS-D). Preclinical studies suggest its role in attenuating myopathic changes in aging rats by activating myogenic stellate cells, reversing gut microbiome dysbiosis and improving faecal metabolite profiles in chronic renal failure, and ameliorating experimental colitis. Its mechanism involves modulating gut microbiota, strengthening the intestinal epithelial barrier, enhancing macrophage phagocytosis, and exhibiting antioxidant activities. The heat-treated form is considered a postbiotic, offering beneficial effects without the risks associated with live microorganisms.
- Brand names
- LacteolLacteol Fort
- Other names
- Lactobacillus acidophilus LBLactobacillus boucardiiLBiome
02
Targets
TA (Teichoic acid)
Beyond the preview
Go deeper on Lactobacillus LB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus LB.